A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

NCT ID: NCT03979313

Last Updated: 2024-02-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

3012 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-23

Study Completion Date

2023-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy late preterm and term infants who are 35 weeks or greater gestational age and entering their first RSV season.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This pivotal Phase 3 study will determine if MEDI8897 will prevent medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy infants entering their first RSV season. The population to be enrolled is healthy late preterm and term infants born 35 weeks 0 days or greater gestational age (GA) who would not be eligible to receive RSV prophylaxis. A total of approximately 3,000 infants will be randomized 2:1 to receive either MEDI8897 or placebo. All subjects will be followed for approximately 510 days after dosing. Enrollment is planned at approximately 350 sites across the USA, Canada, Europe, Asia, and Southern Hemisphere.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Syncytial Virus Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MEDI8897

Anti-RSV monoclonal antibody with an extended half-life

Group Type EXPERIMENTAL

MEDI8897

Intervention Type DRUG

Anti-RSV monoclonal antibody with an extended half-life

Placebo

Commercially available 0.9% (w/v) saline

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Commercially available 0.9% (w/v) saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEDI8897

Anti-RSV monoclonal antibody with an extended half-life

Intervention Type DRUG

Placebo

Commercially available 0.9% (w/v) saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy infants in their first year of life and born at or after 35 weeks 0 days GA
* Infants who are entering their first RSV season at the time of screening

Exclusion Criteria

* Meets national or other local criteria to receive commercial palivizumab
* Any fever (≥ 100.4°F \[≥ 38.0°C\], regardless of route) or acute illness within 7 days prior to randomization
* Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection
* Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination
Minimum Eligible Age

0 Years

Maximum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Fort Defiance, Arizona, United States

Site Status

Research Site

Fayetteville, Arkansas, United States

Site Status

Research Site

Anaheim, California, United States

Site Status

Research Site

Downey, California, United States

Site Status

Research Site

National City, California, United States

Site Status

Research Site

Paramount, California, United States

Site Status

Research Site

West Covina, California, United States

Site Status

Research Site

Aurora, Colorado, United States

Site Status

Research Site

Colorado Springs, Colorado, United States

Site Status

Research Site

Washington D.C., District of Columbia, United States

Site Status

Research Site

Gainesville, Florida, United States

Site Status

Research Site

Hialeah, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Fort Gordon, Georgia, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Oak Lawn, Illinois, United States

Site Status

Research Site

Indianapolis, Indiana, United States

Site Status

Research Site

West Des Moines, Iowa, United States

Site Status

Research Site

Bardstown, Kentucky, United States

Site Status

Research Site

Lexington, Kentucky, United States

Site Status

Research Site

Shreveport, Louisiana, United States

Site Status

Research Site

Jackson, Mississippi, United States

Site Status

Research Site

Columbia, Missouri, United States

Site Status

Research Site

Lincoln, Nebraska, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Gallup, New Mexico, United States

Site Status

Research Site

Shiprock, New Mexico, United States

Site Status

Research Site

Syracuse, New York, United States

Site Status

Research Site

Boone, North Carolina, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Columbus, Ohio, United States

Site Status

Research Site

Dayton, Ohio, United States

Site Status

Research Site

Dayton, Ohio, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Erie, Pennsylvania, United States

Site Status

Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Research Site

Warwick, Rhode Island, United States

Site Status

Research Site

North Charleston, South Carolina, United States

Site Status

Research Site

Sioux Falls, South Dakota, United States

Site Status

Research Site

Kingsport, Tennessee, United States

Site Status

Research Site

Memphis, Tennessee, United States

Site Status

Research Site

Tullahoma, Tennessee, United States

Site Status

Research Site

Baytown, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Edinburg, Texas, United States

Site Status

Research Site

League City, Texas, United States

Site Status

Research Site

Longview, Texas, United States

Site Status

Research Site

Pearland, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

Tomball, Texas, United States

Site Status

Research Site

Layton, Utah, United States

Site Status

Research Site

Roy, Utah, United States

Site Status

Research Site

Salt Lake City, Utah, United States

Site Status

Research Site

Salt Lake City, Utah, United States

Site Status

Research Site

South Jordan, Utah, United States

Site Status

Research Site

St. George, Utah, United States

Site Status

Research Site

Charlottesville, Virginia, United States

Site Status

Research Site

Richmond, Virginia, United States

Site Status

Research Site

Seattle, Washington, United States

Site Status

Research Site

Morgantown, West Virginia, United States

Site Status

Research Site

Marshfield, Wisconsin, United States

Site Status

Research Site

San Miguel de Tucumán, , Argentina

Site Status

Research Site

San Miguel de Tucumán, , Argentina

Site Status

Research Site

Clayton, , Australia

Site Status

Research Site

Nedlands, , Australia

Site Status

Research Site

Graz, , Austria

Site Status

Research Site

Vienna, , Austria

Site Status

Research Site

Bruges, , Belgium

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Ghent, , Belgium

Site Status

Research Site

Montana, , Bulgaria

Site Status

Research Site

Pazardzhik, , Bulgaria

Site Status

Research Site

Pleven, , Bulgaria

Site Status

Research Site

Plovdiv, , Bulgaria

Site Status

Research Site

Plovdiv, , Bulgaria

Site Status

Research Site

Rousse, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Veliko Tarnovo, , Bulgaria

Site Status

Research Site

Calgary, Alberta, Canada

Site Status

Research Site

Vancouver, British Columbia, Canada

Site Status

Research Site

Pierrefonds, Quebec, Canada

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Cali, , Colombia

Site Status

Research Site

Chía, , Colombia

Site Status

Research Site

Medellín, , Colombia

Site Status

Research Site

Medellín, , Colombia

Site Status

Research Site

Montería, , Colombia

Site Status

Research Site

Soledad, , Colombia

Site Status

Research Site

Havlíčkův Brod, , Czechia

Site Status

Research Site

Paide, , Estonia

Site Status

Research Site

Tallinn, , Estonia

Site Status

Research Site

Tallinn, , Estonia

Site Status

Research Site

Tallinn, , Estonia

Site Status

Research Site

Tartu, , Estonia

Site Status

Research Site

Espoo, , Finland

Site Status

Research Site

Helsinki, , Finland

Site Status

Research Site

Järvenpää, , Finland

Site Status

Research Site

Kokkola, , Finland

Site Status

Research Site

Oulu, , Finland

Site Status

Research Site

Pori, , Finland

Site Status

Research Site

Seinäjoki, , Finland

Site Status

Research Site

Tampere, , Finland

Site Status

Research Site

Turku, , Finland

Site Status

Research Site

Amiens, , France

Site Status

Research Site

Bordeaux, , France

Site Status

Research Site

Brest, , France

Site Status

Research Site

Bron, , France

Site Status

Research Site

Caen, , France

Site Status

Research Site

Créteil, , France

Site Status

Research Site

Lille, , France

Site Status

Research Site

Frankenthal, , Germany

Site Status

Research Site

Leipzig, , Germany

Site Status

Research Site

Mannheim, , Germany

Site Status

Research Site

Beersheba, , Israel

Site Status

Research Site

Netanya, , Israel

Site Status

Research Site

Roma, , Italy

Site Status

Research Site

Fukuyama-shi, , Japan

Site Status

Research Site

Kawasaki-shi, , Japan

Site Status

Research Site

Maebashi, , Japan

Site Status

Research Site

Okayama, , Japan

Site Status

Research Site

Osaka, , Japan

Site Status

Research Site

Sapporo, , Japan

Site Status

Research Site

Shizuoka, , Japan

Site Status

Research Site

Yokosuka-shi, , Japan

Site Status

Research Site

Jēkabpils, , Latvia

Site Status

Research Site

Riga, , Latvia

Site Status

Research Site

Riga, , Latvia

Site Status

Research Site

Valmiera, , Latvia

Site Status

Research Site

Valmiera, , Latvia

Site Status

Research Site

Kaunas, , Lithuania

Site Status

Research Site

Kaunas, , Lithuania

Site Status

Research Site

México, , Mexico

Site Status

Research Site

Christchurch, , New Zealand

Site Status

Research Site

Grafton, , New Zealand

Site Status

Research Site

Papatoetoe, , New Zealand

Site Status

Research Site

Wellington, , New Zealand

Site Status

Research Site

Cuidad de Panama, , Panama

Site Status

Research Site

David, , Panama

Site Status

Research Site

La Chorrera, , Panama

Site Status

Research Site

Panama City, , Panama

Site Status

Research Site

Krakow, , Poland

Site Status

Research Site

Krakow, , Poland

Site Status

Research Site

Torun, , Poland

Site Status

Research Site

Wroclaw, , Poland

Site Status

Research Site

Wroclaw, , Poland

Site Status

Research Site

Łęczna, , Poland

Site Status

Research Site

Perm, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Cape Town, , South Africa

Site Status

Research Site

Cape Town, , South Africa

Site Status

Research Site

Cape Town, , South Africa

Site Status

Research Site

Durban, , South Africa

Site Status

Research Site

Johannesburg, , South Africa

Site Status

Research Site

Johannesburg, , South Africa

Site Status

Research Site

Pretoria, , South Africa

Site Status

Research Site

Pretoria, , South Africa

Site Status

Research Site

Rondebosch, , South Africa

Site Status

Research Site

Soweto, , South Africa

Site Status

Research Site

Incheon, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Alicante, , Spain

Site Status

Research Site

Antequera, , Spain

Site Status

Research Site

Castellon, , Spain

Site Status

Research Site

Córdoba, , Spain

Site Status

Research Site

Granada, , Spain

Site Status

Research Site

Leganés, , Spain

Site Status

Research Site

Lleida, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Málaga, , Spain

Site Status

Research Site

Móstoles, , Spain

Site Status

Research Site

Pozuelo de Alarcón, , Spain

Site Status

Research Site

San Cristóbal de La Laguna, , Spain

Site Status

Research Site

Sant Cugat del Vallès, , Spain

Site Status

Research Site

Sant Joan d'Alacant, , Spain

Site Status

Research Site

Santiago de Compostela, , Spain

Site Status

Research Site

Valencia, , Spain

Site Status

Research Site

Linköping, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Adana, , Turkey (Türkiye)

Site Status

Research Site

Ankara, , Turkey (Türkiye)

Site Status

Research Site

Izmir, , Turkey (Türkiye)

Site Status

Research Site

Kocaeli, , Turkey (Türkiye)

Site Status

Research Site

Chernivtsі, , Ukraine

Site Status

Research Site

Dnipro, , Ukraine

Site Status

Research Site

Kyiv, , Ukraine

Site Status

Research Site

Sumy, , Ukraine

Site Status

Research Site

Vinnytsia, , Ukraine

Site Status

Research Site

Liverpool, , United Kingdom

Site Status

Research Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Bulgaria Canada Chile Colombia Czechia Estonia Finland France Germany Israel Italy Japan Latvia Lithuania Mexico New Zealand Panama Poland Russia South Africa South Korea Spain Sweden Turkey (Türkiye) Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Bolanos R, Araos R, Gonzalez C, Sepulveda D, Falconi JF, Averin A, Atwood M, Quinn E, Law AW, Mendes D. Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus. Expert Rev Vaccines. 2025 Dec;24(1):904-913. doi: 10.1080/14760584.2025.2562201. Epub 2025 Oct 2.

Reference Type DERIVED
PMID: 40958705 (View on PubMed)

Arbetter D, Gopalakrishnan V, Aksyuk AA, Ahani B, Chang Y, Dagan R, Esser MT, Hammitt LL, Mankad VS, Saez-Llorens X, Shen D, Leach A, Kelly EJ, Villafana T, Wilkins D. Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY). Clin Infect Dis. 2024 Dec 4:ciae596. doi: 10.1093/cid/ciae596. Online ahead of print.

Reference Type DERIVED
PMID: 39656748 (View on PubMed)

Langer S, Holzapfel S, August L, Badura A, Wellmann S, Mack I. Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence? Vaccine. 2024 Oct 3;42(23):126050. doi: 10.1016/j.vaccine.2024.06.018. Epub 2024 Jun 19.

Reference Type DERIVED
PMID: 38902186 (View on PubMed)

Dagan R, Hammitt LL, Seoane Nunez B, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Chang Y, Currie A, Grenham A, Shroff M, Takas T, Mankad VS, Leach A, Villafana T. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season. J Pediatric Infect Dis Soc. 2024 Feb 26;13(2):144-147. doi: 10.1093/jpids/piad113.

Reference Type DERIVED
PMID: 38219024 (View on PubMed)

Ahani B, Tuffy KM, Aksyuk AA, Wilkins D, Abram ME, Dagan R, Domachowske JB, Guest JD, Ji H, Kushnir A, Leach A, Madhi SA, Mankad VS, Simoes EAF, Sparklin B, Speer SD, Stanley AM, Tabor DE, Hamren UW, Kelly EJ, Villafana T. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023 Jul 19;14(1):4347. doi: 10.1038/s41467-023-40057-8.

Reference Type DERIVED
PMID: 37468530 (View on PubMed)

Muller WJ, Madhi SA, Seoane Nunez B, Baca Cots M, Bosheva M, Dagan R, Hammitt LL, Llapur CJ, Novoa JM, Saez Llorens X, Grenham A, Kelly EJ, Mankad VS, Shroff M, Takas T, Leach A, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5. No abstract available.

Reference Type DERIVED
PMID: 37018470 (View on PubMed)

Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wahlby Hamren U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.

Reference Type DERIVED
PMID: 35235726 (View on PubMed)

Ginsburg AS, Srikantiah P. Respiratory syncytial virus: promising progress against a leading cause of pneumonia. Lancet Glob Health. 2021 Dec;9(12):e1644-e1645. doi: 10.1016/S2214-109X(21)00455-1. Epub 2021 Nov 11. No abstract available.

Reference Type DERIVED
PMID: 34774184 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-000114-11

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D5290C00004

Identifier Type: -

Identifier Source: org_study_id

NCT05238974

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MEDI-557 Adult Dosing
NCT01562938 COMPLETED PHASE1
RSV Challenge in Healthy Adults
NCT00100373 COMPLETED NA